Tag Archive: Bhavya Doshi

Aug 8 2018

New FVIII Center Crosses Disciplines to Reach Answers for Hemophilia A

Hematologists have grappled for many years to understand the basic mechanisms underlying why some young patients with the inherited bleeding disorder hemophilia A develop inhibitory antibodies, also known as factor VIII (FVIII) inhibitors, to protein replacement therapy. The presence of FVIII inhibitors is a serious obstacle that makes it difficult and extremely expensive to treat their hemophilia, leads to complications such as joint disease, and increases mortality.

Such a major challenge requires major brain power. So the National Institutes of Health called on the scientific community to reframe the question: Why is FVIII so immunogenic?

Read the rest of this entry >>

Aug 29 2017

CHOP Scientists Advance Hemophilia Research With Bayer Awards

For children with hemophilia, every new research advance is a step toward a life filled with more activity, freedom, and adventure. The genetic condition, which affects roughly one in 5,000 births, causes children to bleed and bruise more easily than others – meaning that a simple cut, scrape, or small surgery can result in uncontrollable and excessive bleeding. While hemophilia is a lifelong condition, breakthroughs in the laboratory are driving novel treatments, and thanks to recently announced grants from the Bayer Hemophilia Awards Program (BHAP), scientists at Children’s Hospital of Philadelphia will be able to continue conducting even more investigations.

Read the rest of this entry >>